Odense University Hospital

Semaglutide Demonstrates Significant Metabolic Benefits in Schizophrenia Patients on Antipsychotic Therapy

- Semaglutide reduced HbA1c levels by 0.25% compared to placebo in patients with schizophrenia taking second-generation antipsychotics, with nearly 50% achieving low-risk glycemic targets. - Patients experienced substantial weight loss averaging 9.2 kg over 26 weeks, along with significant reductions in waist circumference and fat mass. - The treatment showed no negative impact on psychiatric symptoms or mental health status, with adverse events primarily limited to mild gastrointestinal effects. - The findings suggest early intervention with semaglutide may effectively counteract metabolic complications associated with antipsychotic medications in this vulnerable population.